A single-arm phase II study of olaparib maintenance with pembrolizumab and bevacizumab in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer (OPEB-01)

BACKGROUND: The optimal treatment of BRCA wild-type patients with platinum-sensitive recurrent ovarian cancer remains unknown. Recently, there is an increase in the evidence to support the role of the combination of a poly(adenosine diphosphate-ribose) polymerase inhibitor, anti-angiogenic agents, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Yong Jae, Lim, Myong Cheol, Kim, Byoung-Gie, Ngoi, Natalie YL, Choi, Chel Hun, Park, Sang-Yoon, Tan, David SP, Go, Yunjung, Lee, Jung-Yun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology; Japan Society of Gynecologic Oncology 2021
Materias:
Clinical Trial Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7930449/
https://www.ncbi.nlm.nih.gov/pubmed/33559413
http://dx.doi.org/10.3802/jgo.2021.32.e31

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7930449/
https://www.ncbi.nlm.nih.gov/pubmed/33559413
http://dx.doi.org/10.3802/jgo.2021.32.e31

Ejemplares similares